Zacks: Brokers Expect Zynex, Inc. (NASDAQ: ZYXI) to Report Earnings of $0.05 Per Share
Stock analysts expect Zynex, Inc. (NASDAQ:ZYXI – Get Rating) to report earnings of $0.05 per share for the current quarter, Zacks reports. Three analysts have released earnings estimates for Zynex. The highest EPS estimate is $0.06 and the lowest is $0.04. Zynex reported earnings of ($0.02) per share in the same quarter last year, which would indicate a positive growth rate of 350% year over year. The company is expected to announce its next earnings report on Monday, January 1.
On average, analysts expect Zynex to report annual earnings of $0.50 per share for the current year, with EPS estimates ranging from $0.43 to $0.54. For next year, analysts expect the company to post earnings of $0.72 per share, with EPS estimates ranging from $0.55 to $0.89. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts who provide coverage for Zynex.
Zynex (NASDAQ:ZYXI – Get Rating) last reported results on Thursday, February 24. The company reported earnings per share of $0.23 for the quarter, beating Thomson Reuters consensus estimate of $0.19 by $0.04. Zynex had a return on equity of 27.28% and a net margin of 13.13%. The company posted revenue of $40.37 million in the quarter, versus a consensus estimate of $41.06 million.
ZYXI has been the subject of several analyst reports. TheStreet downgraded Zynex from a “b-” rating to a “c+” rating in a research report on Monday, December 20. HC Wainwright reduced its target price on Zynex from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, February 25. Piper Sandler lowered her target price on Zynex from $13.00 to $7.00 in a Friday, February 25 research report. Zacks Investment Research downgraded Zynex from a “hold” rating to a “sell” rating in a Friday, February 25 report. Finally, B. Riley cut his price target on Zynex from $15.50 to $10.00 and set a “buy” rating for the company in a Monday, February 28 report. One equity research analyst gave the stock a sell rating, one gave the company a hold rating and three gave the company a buy rating. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $14.70.
Hedge funds and other institutional investors have recently changed their positions in the company. Metropolitan Life Insurance Co NY acquired a new stake in Zynex during the third quarter valued at approximately $65,000. Denali Advisors LLC acquired a new stake in Zynex during the fourth quarter valued at approximately $70,000. Nisa Investment Advisors LLC acquired a new stake in Zynex during the fourth quarter valued at approximately $63,000. Keebeck Alpha LP acquired a new stake in Zynex during the third quarter valued at approximately $127,000. Finally, OLD Mission Capital LLC acquired a new stake in Zynex during the third quarter valued at approximately $211,000. Hedge funds and other institutional investors own 27.23% of the company’s shares.
Shares of NASDAQ ZYXI opened at $6.85 on Wednesday. Zynex has a 1-year low of $4.97 and a 1-year high of $16.26. The company has a 50-day moving average of $6.31 and a 200-day moving average of $9.50. The company has a debt ratio of 0.15, a current ratio of 3.62 and a quick ratio of 3.15. The company has a market capitalization of $272.52 million, a price-earnings ratio of 15.60 and a beta of 0.90.
About Zynex (Get a rating)
Zynex, Inc, through its subsidiaries, designs, manufactures and markets medical devices to treat chronic and acute pain; and activating and exercising muscles for rehabilitation purposes with electrical stimulation. The Company offers NexWave, a dual-channel, multi-modality transcutaneous electrical nerve stimulation and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists through field sales representatives; NeuroMove, an electromyography-triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device.
Get a Free Copy of Zacks Research Report on Zynex (ZYXI)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Zynex Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Zynex and related companies with MarketBeat.com’s FREE daily newsletter.